ArticleNeuropharmacology2013
Dopamine D(3) receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice.
Article in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)-VK4-116, as a Non-Opioid Medication for the Treatment of Opioid Use Disorder.Medicinal research reviews · 2026Review
- AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- The influence of dopamine autoreceptors on temperament and addiction risk.Neuroscience and biobehavioral reviews · 2023Review
- Blockade of the Dopamine DNeuroscience bulletin · 2023Article
- Dopamine D3 Receptor Modulates Akt/mTOR and ERKInternational journal of molecular sciences · 2023Article
- Selective D3 receptor antagonism modulates neural response during negative emotional processing in substance dependence.Frontiers in psychiatry · 2022Article
- Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals.Frontiers in neuroscience · 2021Review
- Increased expression of plasma hsa-miR-181a in male patients with heroin addiction use disorder.Journal of clinical laboratory analysis · 2020Article
- (±)VK4-40, a novel dopamine DBritish journal of pharmacology · 2020Article
- Cocaine reward and memory after chemogenetic inhibition of distinct serotonin neuron subtypes in mice.Psychopharmacology · 2020Article
- Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.Neuroscience and biobehavioral reviews · 2020Review
- Newly Developed Dopamine DThe Journal of pharmacology and experimental therapeutics · 2019Article
- The highly selective dopamine DNeuropharmacology · 2019Article
- Dopamine DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
- Dopamine DFrontiers in behavioral neuroscience · 2019Article
- Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.Biological psychiatry · 2018Article
- Optogenetic self-stimulation in the nucleus accumbens: D1 reward versus D2 ambivalence.PloS one · 2018Article
- Examining the role of dopamine D2 and D3 receptors in Pavlovian conditioned approach behaviors.Behavioural brain research · 2016Article
- The dopamine D3 receptor antagonist, SR 21502, facilitates extinction of cocaine conditioned place preference.Drug and alcohol dependence · 2016Article
- A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice.Acta pharmacologica Sinica · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The dopamine (DA) D3 receptor (D3R) has received much attention in medication development for treatment of addiction. However, the functional role of the D3R in drug reward and addiction has been a matter of debate. We recently reported that D3 receptor-knockout (D3(-/-)) mice display increased vulnerability to cocaine self-administration, which we interpret as a compensatory response to attenuated cocaine reward after D3R deletion. Here we report that D3(-/-) mice displayed attenuated cocaine-induced conditioned place response (CPP) compared to wild-type mice. Similarly, blockade of brain D3Rs by YQA-14, a novel DA D3 receptor antagonist, significantly and dose-dependently inhibits acquisition and expression of cocaine-induced CPP in WT mice, but not in D3(-/-) mice. These findings suggest that: 1) D3Rs play an important role in mediating cocaine's rewarding effects; and 2) YQA-14 is a highly potent and selective D3R antagonist in vivo, which deserves further study as a candidate for treatment of cocaine addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.